AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance

U.S. Markets closed

Allergan plc (AGN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
233.99-0.56 (-0.24%)
At close: 4:01PM EDT

233.99 0.00 (0.00%)
After hours: 6:03PM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close234.55
Bid0.00 x
Ask0.00 x
Day's Range233.35 - 236.41
52 Week Range184.50 - 282.59
Avg. Volume3,650,993
Market Cap78.44B
PE Ratio (TTM)6.13
Earnings DateN/A
Dividend & Yield2.80 (1.18%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Allergan, Dow's Apple Lead Q4 Buybacks; Health Care Atop S&P 500
    Investor's Business Daily2 hours ago

    Allergan, Dow's Apple Lead Q4 Buybacks; Health Care Atop S&P 500

    Share repurchases are a popular way to return capital to shareholders, tending to boost a stock and per-share earnings.

  • Investopedia3 hours ago

    Allergan Stock Reacts Well In Downtrodden Sector

    AGN shares have held up well in the last couple of days despite a weak sector.

  • American City Business Journals8 hours ago

    ​Latest Editas research pact could be worth up to $1 billion

    Editas Medicine could earn upwards of $1 billion in milestone payments through a research and development alliance that it recently struck with Allergan, according to a spokeswoman for the Cambridge gene editing firm. Editas (EDIT) announced on March 14 that it would receive $90 million up front in exchange for giving Allergan (AGN) the option to license up to five preclinical programs targeting eye disease — a relatively modest sum. On Wednesday, a spokeswoman for Editas said that the company would be eligible to receive more than $200 million on each program that Allergan exercises its option to license.